日本化学療法学会雑誌第50巻第6号

Similar documents
Feb THE JAPANESE JOURNAL OF ANTIBIOTICS Tebipenem pivoxil 1 1, Meiji Seika 2 Meiji Seika G 3 Meiji Seika Tebipen

日本化学療法学会雑誌第59巻第5号

THE JAPANESE JOURNAL OF ANTIBIOTICS 68 3 June 2015 Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis % 2 S. pneumon

208 ( 2 ) THE JAPANESE JOURNAL OF ANTIBIOTICS 63 _ 3 June 2010 Cefditoren pivoxil (CDTR-PI) MS MS 10%

CHEMOTHERAPY

日本化学療法学会雑誌第57巻第6号

180 ( 64 ) THE JAPANESE JOURNAL OF ANTIBIOTICS June 2011 A b group A Streptococcus: GAS GAS 10 meta-analysis 1) 2,3) GAS potential pathogens Tab


日本化学療法学会雑誌第61巻第6号

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin

Key words: bacterial meningitis, Haemophilus influenzae type b, Streptococcus pneumoniae, rapid diagnosis, childhood

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates

Table 1 Diseases and isolated sources of 59 strains of S. pneumoniae in children Fig. 1 Susceptibility of penicillin-g for S. pneumoniae



Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote

1272 CHEMOTHERAPY MAR. 1975

coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

日本化学療法学会雑誌第60巻第4号


CHEMOTHERAPY

日本化学療法学会雑誌第64巻第4号

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human


Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX


VOL. 34 S-2 CHEMOTH8RAPY 913

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity

CHEMOTHERAPY

日本化学療法学会雑誌第65巻第4号

_02三浦.indd

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

988 CHEMOTHERAPY NOV. 1971

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

Table 1 Characteristics of the study participants in Imari municipal hospital


VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St


Table 1. Antimicrobial drugs using for MIC

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-



CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

日本化学療法学会雑誌第56巻第1号

日本化学療法学会雑誌第55巻第S-1号

05_藤田先生_責

VOL.42 S-1

CHEMOTHERAPY Proteus mirabilis GN-79 Escherichia coli No. 35 Proteus vulgaris GN-76 Pseudomonas aeruginosa No. 11 Escherichia coli ML-1410 RGN-823 Kle

cover

〈企業特集：検査機器・試薬・技術の新たな展開〉新規マイコプラズマ抗原検査キット—プロラスト®Myco

Key words: Antibodies to Leptospira, Tokyo, Uveitis

CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c

Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus


Table1MIC of BAY o 9867 against standard strains


VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega


Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

日本化学療法学会雑誌第59巻第6号

.\...pwd

Key words: Antibiotics, Intestinal bacterial flora, Germfree mouse


56 pp , 2005 * ******* *** ** CA CAMA

VOL.48 NO.7 lase negative staphylococci, Escherichia coli, Klebsiella spp., Citrobacter freundii, Enterobacter spp., indole-positive Proteus, Serratia

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT


感染症学雑誌第77巻第8号

08-g-”O−}„j‹ê-4.02


Key words : Adverse reactions, Egg allergy, IgG antibody, Mills allergy, FAST

日本化学療法学会雑誌第57巻第4号

VOL. 43 NO. 4


日本消化器外科学会雑誌第29巻第9号

DIC vegetation 1 nonbacterial thrombogenic e

40B: Satoshi Shimai 1 and Shigehiro Fujimoto 2 1 Center for Liberal Arts and Education, Minami-Kyushu University, Miyakonojo,

日本消化器外科学会雑誌第31巻第7号

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

国土技術政策総合研究所　研究資料

Key words : influenza, nested-pcr, serotype



日本化学療法学会雑誌第56巻第S-1号

2 94


Transcription:

13 11 30 14 4 22 Streptococcus pneumoniae Haemophilus influenzae amoxicillin AMPC cefditoren pivoxil CDTR AMPC 50 mg kg day CDTR 9mg kg day CDTR 18 mg kg day S. pneumoniae H. influenzae 8 17 25 1 25 S. pneumoniae 18 H. influenzae 4 S. pneumoniae H. influenzae 3 S. pneumoniae 18 S. pneumoniae 2 S. pneumoniae PSSP 2 PISP 4 PRSP 17 H. influenzae lactamase BLNAS 3 lactamase BLNAR 4 2 PSSP PISP AMPC PSSP AMPC PRSP PRSP 17 AMPC 2 4 PRSP 11 3 CDTR 1 AMPC 1 16 CDTR PRSP 1 PRSP 1 PRSP PRSP S. pneumoniae 17 23 9 3 BLNAS 3 AMPC CDTR CDTR 1 BLNAS 1 BLNAS BLNAR 4 AMPC CDTR 2 BLNAR 3 2 1 BLNAR H. influenzae 4 S. pneumoniae H. influenzae AMPC Key words: Streptococcus pneumoniae Haemophilus influenzae acute otitis media nasopharyngeal flora antibiotics Streptococcus pneumoniae Haemophilus influenzae Moraxella catarrhalis 3 70 1 S. pneumoniae H. influenzae 3702 4 2 9 carrier forcus S. pneumoniae H. influenzae

10 10 11 14 S. pneumoniae H. influenzae amoxicillin AMPC cefditoren pivoxil CDTR I 1 S. pneumoniae H. influenzae 25 carrier forcus 10 6 3 10 1 4 8 17 1 1 25 S. pneumoniae H. influenzae 16 2 1 AMPC 50 mg kg day 3 14 CDTR 9mg kg day 3 14 CDTR 18 mg kg day 4 1 3 7 14 2 First bacteriological examination first day antibiotics execution AMPC 50 mg/kg/day Second third day examination forth day antibiotics execution disappear AMPC 50 mg/kg/day remain CDTR 9 mg/kg/day Third seventh day examination eighth day antibiotics execution AMPC 50 mg/kg/day execution disappear CDTR 9 mg/kg/day execution remain CDTR 18 mg/kg/day Forth eleventh day examination twelfth day antibiotics not execution AMPC 50 mg/kg/day execution CDTR 9 mg/kg/day execution CDTR 18 mg/kg/day Fifth fourteenth day examination execution execution execution AMPC: amoxicillin, CDTR: cefditoren-pivoxil Fig. 1 Schedule of bacteriological examination and antibiotic treatment.

3 7 11 14 3 3 7 11 14 Fig. 1 2 PCR PCR S. pneumoniae H. influenzae S. pneumoniae H. influenzae polymerase chain reaction PCR 2 Ubukata 15 16 S. pneumoniae lyta PBP pbp 1 a pbp 2 b pbp 2 x rrna ermam efflux mefe H. influenzae H. influenzae P6 PBP pbp 3 17 II Table 1 25 S. pneumoniae 18 H. influenzae 4 S. pneumoniae H. influenzae 3 S. pneumoniae 18 2 S. pneumoniae S. pneumoniae PSSP 2 2 PISP 4 4 PRSP 17 17 H. influenzae lactamase BLNAS 3 3 lactamase BLNAR 4 4 1 S. pneumoniae H. influenzae Table 1 PSSP 2 AMPC PRSP PRSP CDTR CDTR PSSP PISP 4 3 AMPC PISP 4 PSSP PISP PRSP BLNAS BLNAR PRSP 17 AMPC 2 4 PRSP PRSP 11 1 2 PSSP PRSP CDTR 1 AMPC 1 16 CDTR 1 PRSP PRSP AMPC 1 PRSP CDTR PRSP 17 17 PRSP S. pneumoniae 23 9 S. pneumoniae PRSP BLNAS 3 AMPC CDTR CDTR AMPC CDTR CDTR 1 1 BLNAR 4 AMPC CDTR 2 AMPC CDTR BLNAR 3 2 1 H. influenzae 7 2 2 25 16 Table 1 S. pneumoniae 13 S. pneumoniae 5 1 PSSP PRSP 4 PRSP PRSP

Table 1 1 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Age Gender Day care Clinical result First M antibiotics germ variation germ volume 1 13 boy good AMPC pbp 1a2b2x,ermAM PRSP 2 BLNAS 1 2 19 boy good AMPC pbp 2 x PISP M 1 BLNAS 1 3 17 boy good AMPC pbp 3 BLNAR 1 4 17 boy poor AMPC pbp 1a2b2x,mefE PRSP 2 5 6 boy good AMPC pbp 2 x PISP M 2 6 22 boy good AMPC pbp 1a2b2x PRSP 3 7 8 boy good AMPC pbp 1a2b2x,ermAM PRSP 2 8 12 boy good AMPC pbp 1a2b2x,mefE PRSP 2 9 20 girl good AMPC pbp 3 BLNAR 3 10 13 girl poor AMPC pbp 1a2b2x,mefE PRSP 2 pbp 2 x, ermam PISP M 1 11 8 girl poor AMPC pbp 1a2b2x PRSP 2 12 12 girl good AMPC pbp 3 BLNAR 3 13 10 girl poor AMPC pbp 1a2b2x,mefE PRSP 3 14 21 girl poor AMPC mefe PRSP 2 BLNAS 2 15 7 girl good AMPC pbp 1a2b2x PRSP 2 16 46 girl good AMPC pbp 1a2b2x,mefE PRSP 3 17 11 girl poor AMPC PSSP 3 18 42 girl good AMPC pbp 2 x PISP 3 pbp 1a2b2x,mefE PRSP 1 19 16 girl good AMPC pbp 1a2b2x,mefE PRSP 3 20 16 girl good AMPC pbp 1a2b2x PRSP 3 21 10 girl poor AMPC pbp 1a2b2x,mefE PRSP 3 22 23 girl good AMPC pbp 3 BLNAR 1 23 13 girl good AMPC pbp 1a2b2x,mefE PRSP 3 24 14 girl good AMPC pbp 1a2b2x,ermAM PRSP 2 25 7 girl poor AMPC pbp 1a2b2x PRSP 3 In clinical result good: recovery case from acute otitis media at the last examination, poor: otitis prone case at the last examination In antibiotics AMPC: amoxicillin In germ PSSP: penicillin susceptible S. pneumoniae, PISP: penicillin intermediate resistant S. pneumoniae, PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae, BLNAR: β lactamase netative ampicillin resistant H. influenzae

Table 1 2 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Second Third antibiotics germ variation germ volume antibiotics germ variation germ volume 1 CDTR disappear CDTR disappear BLNAS 1 disappear 2 AMPC disappear AMPC none disappear none 3 AMPC AMPC disappear none 4 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 2 5 AMPC disappear AMPC none 6 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 3 7 CDTR pbp 1a2b2x,ermAM PRSP 2 CDTR pbp 1a2b2x,ermAM PRSP 2 8 CDTR pbp 1a2b2x,mefE PRSP 2 CDTR pbp 1a2b2x,mefE PRSP 2 9 CDTR CDTR pbp 3 BLNAR 1 disappear 10 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 3 disappear none pbp 3, TEM BLNAR 3 disappear 11 CDTR pbp 1a2b2x PRSP 2 CDTR pbp 1a2b2x PRSP 2 BLNAS 1 12 CDTR CDTR pbp 3 BLNAR 1 disappear 13 CDTR pbp 1a2b2x PRSP 2 CDTR pbp 1a2b2x PRSP 2 pbp 3 BLNAR 1 pbp 3 BLNAR 1 14 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 BLNAS 2 BLNAS 1 15 CDTR pbp 1a2b2x PRSP 1 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x,mefE PRSP 2 disappear pbp 3 BLNAR 1 16 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 17 CDTR pbp 1a2b2x PRSP 3 CDTR pbp 1a2b2x PRSP 2 18 CDTR disappear CDTR none pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 19 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR disappear 20 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 3 BLNAR 3 21 CDTR pbp 1a2b2x,mefE,ermAM PRSP 3 CDTR pbp 1a2b2x,mefE,ermAM PRSP 22 AMPC AMPC disappear none 23 CDTR pbp 1a2b2x,mefE PRSP 3 CDTR pbp 1a2b2x,mefE PRSP 2 BLNAS 1 disappear 24 CDTR pbp 1a2b2x,ermAM PRSP 3 CDTR pbp 1a2b2x,ermAM PRSP 3 pbp 3 BLNAR 1 disappear 25 AMPC disappear AMPC none In antibiotics AMPC: amoxicillin, CDTR :cefditoren pivoxil 9 mg kg day CDTR :cefditoren pivoxil 18 mg kg day In germ PISP: penicillin intermediate resistant S. pneumoniae, PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae,blnar: β lactamase netative ampicillin resistant H. influenzae,none: not execution

Table 1 3 Patient s profil and carriage of Streptococcus pneumoniae and Haemophilus influenzae before and after treatment by amoxicillin and cefditoren pivoxil Case Forth Fifth Bacteriological antibiotics germ variation germ volume germ variation germ volume result 1 CDTR 2 AMPC 3 AMPC 4 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 5 AMPC 6 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x,mefE PRSP 3 change 7 CDTR pbp 1a2b2x,ermAM PRSP 2 pbp 1a2b2x,ermAM PRSP 2 remnant 8 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 9 CDTR 10 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x PRSP 3 change 11 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 remnant disappear disappear disappearance 12 CDTR 13 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 change disappear disappear disappearance 14 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 change disappear disappear disappearance 15 CDTR pbp 1a2b2x PRSP 2 pbp 1a2b2x PRSP 2 remnant disappear disappear disappearance 16 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 3 remnant 17 CDTR pbp 1a2b2x PRSP 3 pbp 1a2b2x PRSP 3 change 18 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant 19 CDTR 20 CDTR pbp 1a2b2x,mefE PRSP 3 pbp 1a2b2x,mefE PRSP 3 change pbp 3 BLNAR 1 pbp 3 BLNAR 1 appearance 21 CDTR pbp 1a2b2x,mefE,ermAM PRSP 3 pbp 1a2b2x,mefE,ermAM PRSP 3 change 22 AMPC 23 CDTR pbp 1a2b2x,mefE PRSP 2 pbp 1a2b2x,mefE PRSP 2 remnant none BLNAS 1 appearance 24 CDTR pbp 1a2b2x,ermAM PRSP 3 pbp 1a2b2x,ermAM PRSP 3 remnant 25 AMPC none pbp 1a2b2x,mefE PRSP 3 change In antibiotics AMPC: amoxicillin, CDTR :cefditoren pivoxil 9 mg kg day CDTR :cefditoren pivoxil 18 mg kg day In germ PRSP: penicillin resistant S. pneumoniae, BLNAS: β lactamase negative ampicillin susceptible H. influenzae, BLNAR: β lactamase netative ampicillin resistant H. influenzae,none: not execution

8 H. influenzae 4 AMPC CDTR 1 BLNAR BLNAR CDTR 3 1 25 17 8 17 S. pneumoniae H. influenzae 8 S. pneumoniae 7 S. pneumoniae 2 H. influenzae 2 PRSP S. pneumoniae 1 8 S. pneumoniae H. influenzae S. pneumoniae 2 S. pneumoniae 6 6 2 PSSP AMPC PRSP S. pneumoniae H. influenzae BLNAS 1 BLNAR 2 3 Table 1 III S. pneumoniae S. pneumoniae 1967 Hansman 18 S. pneumoniae PRSP S. pneumoniae 19 1981 20 PRSP 3 9 H. influenzae lactamase lactamase H. influenzae BLNAR 2 17 S. pneumoniae 1988 4 PRSP PISP 3 9 H. influenzae 3 carrier forcus S. pneumoniae H. influenzae 10 10 11 14 carrier forcus S. pneumoniae H. influenzae 1 AMPC CDTR CDTR S. pneumoniae S. pneumoniae PSSP PISP AMPC PSSP 2 PRSP PRSP 17 17 PRSP S. pneumoniae 23 9 8 PSSP PRSP PRSP PRSP

11 CDTR PSSP 2 4 PISP PRSP 12 4 3 PRSP 2 PISP 1 Ghaffar 12 amoxicillin clavulanate CVA AMPC azithromycin AZM CVA AMPC PSSP PISP 75 PRSP 40 AZM AZM 2 3 Cohen 13 14 2 CVA AMPC cefpodoxime proxetil CPDX 13 2 CVA AMPC ceftriaxone CTRX 14 CVA AMPC CPDX 13 CPDX 107 S. pneumoniae 97 57 PSSP 58 PISP 27 PRSP 12 PSSP 15 PISP 27 PRSP 15 CVA AMPC 185 S. pneumoniae 104 37 PSSP 59 PISP 25 PRSP 20 PSSP 9 PISP 15 PRSP 13 57 37 94 24 PSSP 14 2 8 42 PISP 20 11 11 28 PRSP 22 3 3 CTRX CVA AMPC 14 CTRX 247 S. pneumoniae 143 99 PSSP 65 PISP 37 PRSP 4 PSSP 36 PISP 23 PRSP 40 CVA AMPC 250 S. pneumoniae 151 41 PSSP 71 PISP 32 PRSP 48 PSSP 7 PISP 12 PRSP 22 CTRX 99 CVA AMPC 41 CTRX 99 36 PSSP 21 6 9 23 PISP 15 6 2 40 PRSP 25 9 6 CVA AMPC 41 7 PSSP 2 3 2 12 PISP 8 2 2 22 PRSP 18 3 1 PSSP PISP PRSP S. pneumoniae PSSP PSSP PSSP PISP AMPC CDTR PISP H. influenzae 7 BLNAS AMPC CDTR CDTR 1 BLNAR AMPC CDTR 2 BLNAS BLNAR 1 11 CDTR CDTR 7 4 3 Ghaffar 12 CVA AMPC AZM CVA AMPC lactamase H. influenzae 7 2 lactamase H. influenzae 10 8 AZM lactamase H. influenzae 9 2 lactamase H. influenzae 13 4 Cohen 13 14 CVA AMPC CPDX 13 CVA AMPC CTRX 14 CVA AMPC CPDX 13 CVA AMPC lactamase H. influenzae 32 4 lactamase H. influenzae 43 4 CPDX lactamase

H. influenzae 26 4 lactamase H. influenzae 46 9 CVA AMPC CTRX 14 CVA AMPC lactamase H. influenzae 38 4 lactamase H. influenzae 60 17 CTRX lactamase H. influenzae 34 11 lactamase H. influenzae 64 20 11 14 11 lactamase H. influenzae Ghaffar 12 Cohen 13 14 lactamase BLNAS BLNAR lactamase H. influenzae BLNAR 2 PISP PRSP 21 25 16 13 PSSP PISP 1 PRSP 11 PRSP 13 13 5 5 PRSP S. pneumoniae 1 PSSP PRSP 4 PRSP PRSP PRSP PRSP H. influenzae 4 4 BLNAR AMPC CDTR CDTR 1 BLNAR CDTR 3 S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae Ghaffar 12 CVA AMPC 64 48 75 16 25 PRSP 48 3 16 5 AZM 68 44 65 24 35 PRSP 44 9 24 9 CVA AMPC AZM S. pneumoniae PRSP S. pneumoniae S. pneumoniae S. pneumoniae Ghaffar 12 S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae S. pneumoniae AMPC CDTR CDTR S. pneumoniae H. influenzae

1 : Haemophilus influenzae, Streptococcus pnemoniae Moraxella catarrhalis Jap J Antibiotics 50: 768 775 1997 2 : 16 S 2 : 66 73 2000 3 : 16: 1655 1661 2000 4 : 19: 241 243 1989 5 : 1 8: 58 63 1990 6 : 12: 79 84 1994 7 : JOHNS 13: 1147 1151 1997 8 : 101: 1075 1081 1998 9 : 47: 30 34 1999 10 : 82: 751 757 1979 11 : 49 S A : 153 2001 12 Ghaffar F, Stella L, Katz K, et al.: Effects of Amoxicillin Clavulanate or Azithromycin on nasopharyngeal Carriage of Streptococcus pneumoniae and Haemophilus influenzae in Children with Otitis Media. Clin Infect Dis 31: 875 880 2000 13 Cohen R Bingen E Varon E et al.: Change in nasopharyngeal carriage of Streptococcus pneumoniae resulting from antibiotic therapy for acute otitis media in children. Pediatr Infect Dis J 16: 555 560 1997 14 Cohen R, Navel M, Grunberg J, et al.: One dose ceftriaxone vs. ten days of amoxicillin clavulanate therapy for acute otitis media: clinical efficancy and change in nasopharyngeal flora. Pediatr Infect Dis J 18: 403 409 1999 15 Ubukata K, Muraki T, Igarashi A, et al.: Identification of penicillin and Other Beta Lactam Resistance in Streptococcus pneumoniae using Polymerase Chain Reaction. J Infect Chemother 3: 190 197 1977 16 Ubukata K, Iwata S, Sunakawa K, et al.: In Vitro Activities of New Ketolide HMR 3647 and Other Macrolide Antibiotics Against Streptococcus pneumoniae Having ermam and Genes that Mediate macrolide. Antimicrob Agents Chemother in press 17 : BLNAR 9: 22 25 1999 18 Hansman D, Bullen M M: A resistant pneumococcus. Lancet 2: 264 265 1967 19 Jacobs M R Koornhof H J Robins Browne R M et al.: Emergence of multiply resistant pneumococci. NEngl J Med 299: 735 740 1978 20 : Jap J Antibiotics 34: 95 105 1981 21 : 92: 1071 1079 1999

Changes in nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae from amoxicillin and cefditoren pivoxil therapy in children with acute otitis media Yoshihumi Uno UNO ENT Clinic 3702 1 Tomihara Okayama 701 1153 Japan Acute otitis media is one of the most common upper respiratory infection diseases in childhood. The most common organisms causing it are Streptococcus pneumoniae and Haemophilus influenzae In children the nasopharynx is the carrier focus for upper respiratory infection diseases such as acute otitis media, and S. pneumoniae and H. influenzae colonize the nasopharynx. We studied the changes in nasopharyngeal carriage of S. pneumoniae and H. influenzae before and after amoxicillin AMPC and cefditoren pivoxil CDTR therapy using a polymerase chain reaction to detect penicillin binding protein genes and macroride resistant genes with the following results: 1. In 25 cases 18 showed S. pneumoniae only 4 H. influenzae only and 3 detected cases. In the 18 having only S. pneumoniae 2 consisted of a different type of S. pneumoniae In 23 strains of S. pneumoniae 2 were penicillin susceptible S. pneumoniae PSSP 4 penicillin intermediate resistant S. pneumoniae PISP and 17 penicillin resistant S. pneumoniae PRSP In the 7 strains of H. influenzae 3 were lactamase negative ampicillin susceptible H. influenzae BLNAS and 4 lactamase negative ampicillin resistant H. influenzae BLNAR 2. All PSSP and PISP were removed from the nasopharynx with AMPC but in PSSP PRSP was detected in all cases after AMPC therapy. In the 17 strains of PRSP recognized initially 2 wereremoved from the nasopharynx with AMPC therapy 4changed to other strain types with AMPC therapy and of the 11 strains remaining 3 new strains appeared. With CDTR 9mg kg day therapy 2 strains were removed and 16 remained. With CDTR 18 mg kg day therapy 1 strainchanged to another type and 1newstrainappeared. Ultimately 17 strains remained but only 9 existed from the beginning. 3. All 3 BLNAS strains were removed from the nasopharynx with AMPC CDTR 9mg kg day and CDTR 18 mg kg day therapy. During these therapies however 3 BLNASappeared and only 1 strain ultimately remained in the nasopharynx. All 4 BLNAR strains were removed from the nasopharynx with AMPC with 3 new strains appearing and CDTR 18 mg kg day with 2 new strains appearing. One strain ultimately remained in the nasopharynx. All strains recognized initially were removed. 4. No relationship was seen between S. pneumoniae and H. influenzae remaining in the nasopharynx and results of acute otitis media therapy. But it was recognized the tendencies that in the good result cases the rate of the removal of the bacteria from the beginning were high and allofthem removed with AMPC and in the poor result cases the removal of the bacteria fromthebeginning were not high and bacteria from the beginning changed to the different bacteria which had different pattern of the resistant genes.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック